Source: News-Medical.net — 2026-08-11
Summary
Leica Biosystems received FDA 510(k) clearance for Aperio iQC DX, described as the industry's first standalone AI-assisted quality-control software for digital pathology, alongside clearances for two new Aperio whole-slide scanners. The software automatically screens digitized slides for six common imaging artifacts — including air bubbles, pen marks, clipped or missing tissue, out-of-focus regions, and image striping — while the slide is still on the scanner. In real-world data cited by the company, the AI caught up to 24% more artifacts than histotechnicians working alone and cut hands-on review time by 69%.
Key Takeaways
- Aperio iQC DX checks for six specific artifact types (air bubbles, pen marks, clipped tissue, missing tissue, out-of-focus regions, image striping) automatically while a slide is still on the scanner, rather than after a pathologist has already started reviewing it.
- Real-world performance data showed the AI detected up to 24% more artifacts than histotechnicians caught on their own — meaning a meaningful share of quality issues were previously slipping through manual review.
- The same real-world data showed a 69% reduction in hands-on review time, a substantial workflow efficiency gain for pathology labs processing high slide volumes.
- Catching artifacts at the scanning stage, before a case reaches a pathologist, reduces the risk of a diagnosis being delayed or based on a compromised image — directly tying the QC software to diagnostic turnaround time.
- The clearance bundle also included two new Aperio whole-slide scanners, positioning Leica Biosystems to sell an integrated hardware-plus-AI-QC pipeline rather than software alone.
Reel Script
Hook: A blurry patch or a stray air bubble on a pathology slide can throw off a cancer diagnosis, and until now catching those flaws depended entirely on a technician's eyes. The FDA just cleared software that catches more of them, and does it 69% faster.
Core Concept: Digital pathology turns physical tissue slides into high-resolution scanned images that pathologists review on screen instead of under a microscope. But scanning introduces its own failure points — an air bubble trapped under the coverslip, a pen mark, tissue that got clipped or displaced, a region that came out of focus — and until now, spotting these artifacts fell to histotechnicians manually scanning through images before handoff. Aperio iQC DX automates that check: it's AI software that screens for six specific artifact types while the slide is still sitting in the scanner, flagging problems before the case ever reaches a pathologist's queue. The goal isn't replacing the technician's judgment — it's catching what tired eyes miss at high volume, at the earliest possible point in the pipeline.
Hands-On: The metric worth putting on screen is the real-world performance data behind the clearance: the AI caught up to 24% more artifacts than histotechnicians working alone — air bubbles, pen marks, clipped or missing tissue, out-of-focus regions, and image striping, the six categories the software screens for automatically. The second number is the workflow payoff: hands-on review time dropped 69% in the same real-world data set, which for a high-volume pathology lab translates directly into faster case turnaround. Leica Biosystems paired the software clearance with FDA clearances for two new Aperio whole-slide scanners in the same announcement, meaning the artifact-detection layer isn't a bolt-on for existing hardware — it's being positioned as part of an integrated scan-and-check pipeline.
Takeaway: Quality control is one of the least glamorous but most consequential places to put AI in pathology, because a missed artifact isn't a UX annoyance — it's a potential misdiagnosis. A 24% jump in artifact detection paired with a 69% cut in review time is a genuinely strong efficiency case; the thing to watch next is whether independent labs replicate those numbers outside Leica's own reported data.